The stock of Adverum Biotechnologies Inc (NASDAQ:ADVM) last traded at $2.29, down -1.29% from the previous session.
ADVM stock price is now -16.63% away from the 50-day moving average and -54.43% away from the 200-day moving average. The market capitalization of the company currently stands at $47.84M.
With the price target of $25, Oppenheimer recently initiated with Outperform rating for Adverum Biotechnologies Inc (NASDAQ: ADVM). On April 30, 2024, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $30, while ‘Truist’ rates the stock as ‘Buy’
In other news, Soparkar Peter, CHIEF OPERATING OFFICER sold 2,960 shares of the company’s stock on May 15 ’25. The stock was sold for $5,920 at an average price of $2.00. Upon completion of the transaction, the CHIEF OPERATING OFFICER now directly owns 39,154 shares in the company, valued at $89662.66. An SEC document containing details of the transaction can be found on the SEC’s website. On May 15 ’25, CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh sold 924 shares of the business’s stock. A total of $1,848 was realized by selling the stock at an average price of $2.00. This leaves the insider owning 13,768 shares of the company worth $31528.72. A total of 33.78% of the company’s stock is owned by insiders.
During the past 12 months, Adverum Biotechnologies Inc has had a low of $1.78 and a high of $10.14. As of last week, the company has a debt-to-equity ratio of 3.53, a current ratio of 3.57, and a quick ratio of 3.57.
The net profit margin was -13356.00% and return on equity was -127.99% for ADVM.
